1. Home
  2. AKRO vs CENT Comparison

AKRO vs CENT Comparison

Compare AKRO & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • CENT
  • Stock Information
  • Founded
  • AKRO 2017
  • CENT 1955
  • Country
  • AKRO United States
  • CENT United States
  • Employees
  • AKRO N/A
  • CENT N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • CENT Consumer Specialties
  • Sector
  • AKRO Health Care
  • CENT Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • CENT Nasdaq
  • Market Cap
  • AKRO 2.8B
  • CENT 2.4B
  • IPO Year
  • AKRO 2019
  • CENT N/A
  • Fundamental
  • Price
  • AKRO $39.85
  • CENT $35.04
  • Analyst Decision
  • AKRO Strong Buy
  • CENT Strong Buy
  • Analyst Count
  • AKRO 9
  • CENT 3
  • Target Price
  • AKRO $76.29
  • CENT $45.00
  • AVG Volume (30 Days)
  • AKRO 1.1M
  • CENT 128.1K
  • Earning Date
  • AKRO 05-16-2025
  • CENT 05-07-2025
  • Dividend Yield
  • AKRO N/A
  • CENT N/A
  • EPS Growth
  • AKRO N/A
  • CENT N/A
  • EPS
  • AKRO N/A
  • CENT 1.87
  • Revenue
  • AKRO N/A
  • CENT $3,155,810,000.00
  • Revenue This Year
  • AKRO N/A
  • CENT $2.74
  • Revenue Next Year
  • AKRO N/A
  • CENT $2.16
  • P/E Ratio
  • AKRO N/A
  • CENT $18.64
  • Revenue Growth
  • AKRO N/A
  • CENT N/A
  • 52 Week Low
  • AKRO $17.86
  • CENT $32.16
  • 52 Week High
  • AKRO $58.40
  • CENT $47.48
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 44.56
  • CENT 46.93
  • Support Level
  • AKRO $41.60
  • CENT $32.16
  • Resistance Level
  • AKRO $46.47
  • CENT $35.37
  • Average True Range (ATR)
  • AKRO 2.26
  • CENT 1.14
  • MACD
  • AKRO 0.08
  • CENT 0.03
  • Stochastic Oscillator
  • AKRO 21.84
  • CENT 63.75

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About CENT Central Garden & Pet Company

Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.

Share on Social Networks: